Antiangiogenics meet nanotechnology.
A mutant Raf-1 gene loaded onto nanoparticles, delivered to tumor vasculature with an integrin binding compound, provides effective antiangiogenic gene therapy in mice.
The Burnham Institute, La Jolla, California 92037, USA. ruoslahti@burnham.org
Erkki
E
Ruoslahti
D000818:Animals; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D039302:Integrin alphaVbeta3 / Q000378:metabolism; D051379:Mice; D008863:Microspheres; D036103:Nanotechnology; D009369:Neoplasms / Q000098:blood supply / Q000235:genetics* / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000235:genetics* / Q000628:therapy*; D009928:Organ Specificity; D019908:Proto-Oncogene Proteins c-raf / Q000235:genetics* / Q000378:metabolism*
D039302:Integrin alphaVbeta3; D019908:Proto-Oncogene Proteins c-raf